• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

June-July 2025: Upcoming NCPA Items for Pharmacy Teams

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

FDA Grants De Novo Authorization to 5-Year Breast Cancer Risk Prediction Device

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Clarity Breast’s FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies. Read More

‘Freedom From the Need’: A Pharmacist’s Journey from Constant Hemophilia B Treatment to Gene Therapy

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence. Read More

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments. Read More

Streamlining GLP-1 Prior Authorizations: Innovations in Electronic Prior Authorization Technology

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications. Read More

New Programs Aim to Improve Implementation of Cardiovascular Interventions

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions. Read More
« Older Entries
Next Entries »

Recent Content

  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT